Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NMRA

Neumora Therapeutics Inc

Nov 04 • 04:00PM ET

2.79

-0.22 -7.31 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF SCHA IBB PRFZ VHT SCHB BTEC AVSC IBBQ

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	66.44%	Shs Outstand	161.95M	Perf Week	7.72%
Market Cap	451.83M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	5.64%	Shs Float	52.42M	Perf Month	47.62%
Enterprise Value	254.20M	PEG	-	EPS next Q	-0.33	Inst Own	22.80%	Short Float	12.95%	Perf Quarter	75.47%
Income	-252.09M	P/S	-	EPS this Y	8.44%	Inst Trans	-7.80%	Short Ratio	5.19	Perf Half Y	314.68%
Sales	0.00M	P/B	2.47	EPS next Y	27.71%	ROA	-80.25%	Short Interest	6.79M	Perf YTD	-73.68%
Book/sh	1.13	P/C	2.08	EPS next 5Y	12.12%	ROE	-89.37%	52W High	14.09 -80.20%	Perf Year	-75.63%
Cash/sh	1.34	P/FCF	-	EPS past 3/5Y	0.69% -	ROIC	-124.38%	52W Low	0.61 356.63%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.71% 10.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.84%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.54	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.62	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	10.54	EPS Q/Q	11.67%	SMA20	25.17%	Beta	3.01	Target Price	8.50
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	45.25%	Rel Volume	1.75	Prev Close	3.01
Employees	110	LT Debt/Eq	0.11	Earnings	Aug 06 AMC	SMA200	97.89%	Avg Volume	1.31M	Price	2.79
IPO	Sep 15, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.99% -	Trades		Volume	2,295,202	Change	-7.31%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy	$14
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Nov-03-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire)
Oct-30-25 11:29PM	Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating (Insider Monkey) +17.20%
Oct-27-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 (GlobeNewswire)
06:30AM	Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model (GlobeNewswire)
Oct-01-25 07:00AM	Neumora Therapeutics to Host Virtual R&D Day on October 27 (GlobeNewswire)
09:40AM	Loading…
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks)
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-02-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in September (GlobeNewswire)
Aug-20-25 12:13AM	Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 (Insider Monkey)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive) -11.52%
Aug-06-25 04:05PM	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
03:10AM	Loading…
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
10:33AM	Loading…
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:22 PM
ARCH Venture Partners XII, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:21 PM
ARCH Venture Partners X, LLC	10% Owner	Oct 27 '25	Buy	2.61	1,915,700	4,999,977	6,046,907	Oct 29 07:19 PM
Henry Gosebruch	Officer	Mar 12 '25	Proposed Sale	1.43	15,000	21,450		Mar 12 04:49 PM
BERNS PAUL L	See Remarks	Feb 18 '25	Sale	1.69	13,871	23,468	7,405,004	Feb 20 05:14 PM
Milligan Michael Lee	See Remarks	Feb 18 '25	Sale	1.69	1,978	3,351	22,470	Feb 20 05:14 PM
Aurora Daljit Singh	Chief Strategy Officer	Feb 18 '25	Sale	1.68	8,565	14,347	88,935	Feb 20 05:13 PM
Lenz Robert A.	Head of R&D	Feb 18 '25	Sale	1.67	5,614	9,383	309,092	Feb 20 05:12 PM
Pinto Joshua	President	Feb 18 '25	Sale	1.67	8,048	13,477	76,952	Feb 20 05:11 PM
Suh Carol Y.	Officer	Feb 18 '25	Proposed Sale	1.68	9,540	16,020		Feb 18 05:51 PM
Milligan Michael Lee	Officer	Feb 18 '25	Proposed Sale	1.69	1,978	3,351		Feb 18 05:49 PM
Pinto Joshua	Officer	Feb 18 '25	Proposed Sale	1.67	8,048	13,478		Feb 18 05:45 PM
Lenz Robert A.	Officer	Feb 18 '25	Proposed Sale	1.67	5,614	9,383		Feb 18 05:43 PM
Gosebruch Henry O	Officer	Feb 18 '25	Proposed Sale	1.67	6,857	11,462		Feb 18 05:41 PM
BERNS PAUL L	Officer	Feb 18 '25	Proposed Sale	1.69	13,871	23,468		Feb 18 05:40 PM
Aurora Daljit Singh	Officer	Feb 18 '25	Proposed Sale	1.68	8,565	14,348		Feb 18 05:38 PM

Open in Screener

PRME

Prime Medicine Inc

Nov 04 • 04:00PM ET

4.30

-0.26 -5.70 %

Healthcare • Biotechnology • USA • NASD

PRME Prime Medicine Inc daily Stock Chart

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: ARKG VTI IWM VXF IWN IBB DWAS VTWO VHT SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	48.57%	Shs Outstand	134.49M	Perf Week	-10.79%
Market Cap	766.24M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	14.44%	Shs Float	91.65M	Perf Month	-29.28%
Enterprise Value	784.23M	PEG	-	EPS next Q	-0.25	Inst Own	23.41%	Short Float	17.21%	Perf Quarter	5.65%
Income	-199.28M	P/S	154.48	EPS this Y	28.25%	Inst Trans	0.77%	Short Ratio	4.22	Perf Half Y	223.31%
Sales	4.96M	P/B	9.50	EPS next Y	23.72%	ROA	-73.98%	Short Interest	15.77M	Perf YTD	47.26%
Book/sh	0.45	P/C	7.53	EPS next 5Y	20.49%	ROE	-154.81%	52W High	6.94 -38.04%	Perf Year	10.82%
Cash/sh	0.57	P/FCF	-	EPS past 3/5Y	4.95% -124.13%	ROIC	-114.96%	52W Low	1.11 287.39%	Perf 3Y	-76.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-37.86%	Volatility	9.89% 10.69%	Perf 5Y	-
Dividend TTM	-	EV/Sales	158.11	EPS Y/Y TTM	24.90%	Oper. Margin	-4116.57%	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.56	Sales Y/Y TTM	739.42%	Profit Margin	-4016.83%	RSI (14)	40.56	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	3.56	EPS Q/Q	12.30%	SMA20	-20.27%	Beta	2.66	Target Price	6.71
Payout	-	Debt/Eq	1.97	Sales Q/Q	-	SMA50	-12.69%	Rel Volume	0.83	Prev Close	4.56
Employees	214	LT Debt/Eq	1.85	Earnings	Aug 07 BMO	SMA200	40.09%	Avg Volume	3.74M	Price	4.30
IPO	Oct 20, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.74% -73.30%	Trades		Volume	3,103,280	Change	-5.70%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

Nov-03-25 08:01AM	Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (GlobeNewswire) -7.69%
Oct-30-25 04:01PM	Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy (GlobeNewswire) +13.56%
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV) +9.88%
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:50PM	Loading…
Sep-15-25 04:50PM	Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) (Barchart) +16.46%
Aug-26-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 09:10AM	Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -9.58%
08:00AM	Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-25 04:01PM	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.02% +11.39%
Jul-31-25 11:40PM	JonesTrading Maintains a Buy on Prime Medicine (PRME) (Insider Monkey)
Jul-30-25 09:33PM	Prime Medicine Announces Pricing of Public Offering (GlobeNewswire)
04:01PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
12:35AM	Loading…
Jul-20-25 12:35AM	BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT (Insider Monkey)
Jul-16-25 08:10AM	Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy (Business Wire) -5.83%
07:00AM	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis (GlobeNewswire)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com) +22.19%
Jul-06-25 04:01AM	Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data (Insider Monkey)
May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
10:51AM	Loading…
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GV 2021 GP, L.L.C.	10% Owner	Aug 01 '25	Buy	3.30	1,500,000	4,950,000	3,262,440	Aug 05 04:07 PM
NELSEN ROBERT	Director	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:19 PM
ARCH Venture Partners X, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01 07:18 PM
Liu David R.	10% Owner	Jun 30 '25	Buy	2.52	21,000	52,830	20,240,945	Jul 01 04:03 PM
Liu David R.	10% Owner	Jun 23 '25	Buy	2.16	21,000	45,402	20,219,945	Jun 23 04:33 PM
Liu David R.	10% Owner	Jun 16 '25	Buy	1.49	21,000	31,196	20,198,945	Jun 16 05:14 PM
Liu David R.	10% Owner	Jun 11 '25	Buy	1.60	21,000	33,590	20,177,945	Jun 12 04:49 PM
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22 04:22 PM
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22 04:21 PM
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22 04:18 PM

Open in Screener

MTSR

Metsera Inc

Nov 04 • 04:00PM ET

73.18

+12.45 20.50 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI XBI IWM VB VBK VXF SCHA IWO VTWO IWN

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	54.41%	Shs Outstand	104.89M	Perf Week	39.60%
Market Cap	7.71B	Forward P/E	-	EPS next Y	-3.60	Insider Trans	-0.00%	Shs Float	48.00M	Perf Month	39.39%
Enterprise Value	7.18B	PEG	-	EPS next Q	-0.72	Inst Own	34.49%	Short Float	10.15%	Perf Quarter	118.91%
Income	-	P/S	-	EPS this Y	79.23%	Inst Trans	5.20%	Short Ratio	2.15	Perf Half Y	221.81%
Sales	-	P/B	17.09	EPS next Y	-19.60%	ROA	-	Short Interest	4.87M	Perf YTD	176.15%
Book/sh	4.28	P/C	14.51	EPS next 5Y	32.84%	ROE	-	52W High	66.10 10.71%	Perf Year	-
Cash/sh	5.04	P/FCF	-	EPS past 3/5Y	-1497.55% -	ROIC	-	52W Low	12.30 494.96%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.19% 1.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	84.20	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	-239.61%	SMA20	32.60%	Beta	-	Target Price	57.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	54.62%	Rel Volume	4.30	Prev Close	60.73
Employees	81	LT Debt/Eq	0.00	Earnings	Jul 28 AMC	SMA200	118.57%	Avg Volume	2.26M	Price	73.18
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.29% -	Trades		Volume	9,731,266	Change	20.50%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$54
Sep-09-25	Initiated	Leerink Partners	Outperform	$77
Jun-20-25	Initiated	Wells Fargo	Overweight	$65
Feb-25-25	Initiated	Guggenheim	Buy	$56
Feb-25-25	Initiated	Evercore ISI	Outperform
Feb-25-25	Initiated	BofA Securities	Buy	$38

Today 04:37PM	How major US stock indexes fared Tuesday, 11/4/2025 (Associated Press Finance) +20.50%
04:30PM	Novo Nordisk Reports Earnings on Wednesday. What to Expect. (Barrons.com)
04:12PM	Novo Sweetens Its Bid For Metsera As Takeover Drama With Pfizer Escalates (Investor's Business Daily)
02:39PM	These Stocks Are Moving the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com)
02:39PM	Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup (The Wall Street Journal)
01:11PM	Loading…
01:11PM	Pfizer Profit Falls Amid Lower Covid-19 Drug Demand (The Wall Street Journal)
01:09PM	Pfizer and Novo Nordisk both raise bids for Metsera (CNBC TV)
12:26PM	Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera (Barrons.com)
11:18AM	Stock Market Today: Stocks Continue Sinking As Rally Hopes Fade, Gov't Shutdown Ties 35 Day Record (TheStreet)
11:15AM	Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools (Zacks)
10:59AM	Pfizer & Novo boost Metsera bids, Hertz stock skyrockets (Yahoo Finance Video)
10:47AM	Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion (Investor's Business Daily)
10:38AM	Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer (Associated Press Finance)
10:22AM	Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle (Bloomberg)
09:58AM	Novo Nordisk Sweetens Offer for Metsera (The Wall Street Journal)
09:09AM	Loading…
09:09AM	Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior" (PR Newswire)
07:20AM	Pfizer raises and narrows full-year earnings guidance (Investing.com)
Nov-03-25 04:11PM	Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. (Barrons.com)
01:23PM	Did Novo Nordisk Just Say "Checkmate" to Pfizer? (Motley Fool)
12:47PM	Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo (Investor's Business Daily)
12:15PM	Pfizer files second lawsuit to block Novo Nordisks $9bn Metsera bid (Financial Times)
12:03PM	Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera (Barrons.com)
11:02AM	Metsera Issues Statement in Response to Litigation (PR Newswire)
09:34AM	Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal (Yahoo Finance Video)
09:19AM	Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera (The Wall Street Journal)
07:44AM	Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war (Pharmaceutical Technology)
06:43AM	Stocks to Watch Monday: Kenvue, Kimberly-Clark, Berkshire Hathaway (The Wall Street Journal)
04:46AM	Meet the 7% Yield Dividend Stock That Could Soar in 2026 (Motley Fool)
01:35AM	Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover (Insider Monkey)
Nov-02-25 05:30AM	Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk (The Wall Street Journal)
11:46AM	Loading…
Nov-01-25 11:46AM	Pfizer sues Metsera, Novo in effort to enforce buyout deal (BioPharma Dive)
Oct-31-25 06:44PM	Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal (The Wall Street Journal)
06:24PM	Metsera Issues Statement in Response to Litigation (PR Newswire)
05:30PM	Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal (Investor's Business Daily)
05:28PM	Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk (Associated Press Finance)
03:50PM	Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition (Business Wire)
12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:07AM	Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results? (Zacks)
10:28AM	Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs (Reuters Videos)
10:03AM	Metsera (MTSR) Soars to All-Time High on Pfizer, Novo Billion-Dollar Bidding War (Insider Monkey)
08:03AM	Massive sales for weight loss drugs spur Eli Lillys Q3 (Pharmaceutical Technology)
05:50AM	Bull market not solely driven by AI. M&A is starting to heat up. (MarketWatch)
Oct-30-25 06:53PM	Mizuho's Holtz talks what is behind Novo's bid for Metsera (CNBC TV) +22.06%
04:47PM	These Stocks Moved the Most Today: Meta, Microsoft, Alphabet, FMC, C.H. Robinson Worldwide, Roblox, Metsera, Chipotle, and More (Barrons.com)
04:35PM	Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
04:13PM	Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera (Investor's Business Daily)
03:03PM	Novo Nordisk takes on Pfizer in bid for obesity biotech Metsera (Reuters Videos)
02:16PM	Pfizer said to mull suing Novo Nordisk over Metsera bid (Investing.com)
02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com)
02:10PM	These Stocks Are Moving the Most Today: Meta, Microsoft, Alphabet, FMC, C.H. Robinson Worldwide, Roblox, Metsera, Chipotle, and More (Barrons.com)
01:31PM	Bidding war rises over weight loss drug that could prevent Ozempic face (The Telegraph)
01:11PM	Chipotle drags fast casual stocks lower, Meta reports raising $125B (Yahoo Finance Video)
12:52PM	Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera (The Wall Street Journal)
12:27PM	Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
11:23AM	Novo Nordisk locks horns with Pfizer in late bid for Metsera (Pharmaceutical Technology)
10:41AM	Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
10:39AM	Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war (Associated Press Finance)
10:04AM	Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle (Bloomberg)
09:25AM	Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook (Yahoo Finance Video)
09:13AM	Novo Nodrisk stock dips on aggressive odder to buy Metsera, reckless says Pfizer (Investing.com)
08:20AM	Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera (AFP)
07:57AM	Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings (The Wall Street Journal)
07:11AM	Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. (Barrons.com)
07:07AM	Metsera Receives Unsolicited Proposal from Novo Nordisk (PR Newswire)
06:57AM	Pfizer Addresses Proposal for Metsera (Business Wire)
06:32AM	Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing (Pharmaceutical Technology)
06:23AM	Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera (The Wall Street Journal)
Oct-27-25 06:24AM	Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most. (Motley Fool)
Oct-13-25 08:45AM	Where Will Pfizer Be in 5 Years? (Motley Fool)
05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-07-25 09:30AM	Down 50%, Should You Buy the Dip on Pfizer? (Motley Fool)
Oct-06-25 04:59AM	3 Reasons to Buy Pfizer Stock Now (Motley Fool)
Oct-02-25 07:02AM	3 Things You Need to Know if You Buy Pfizer Today (Motley Fool)
Sep-30-25 11:02AM	Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. (Barrons.com)
07:50AM	Metsera strengthens case for Pfizer buyout with latest study data (BioPharma Dive)
04:00AM	Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out (Motley Fool)
Sep-29-25 04:01PM	Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 (GlobeNewswire)
Sep-28-25 10:58AM	Down 55%, Should You Buy the Dip on Pfizer? (Motley Fool)
Sep-27-25 08:15AM	Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? (Motley Fool)
Sep-26-25 04:33PM	Pfizer is Locking in New Growth Through a New Acquisition (MarketBeat)
08:45AM	Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock? (Motley Fool)
Sep-25-25 09:35AM	Metsera downgraded to Market Perform from Outperform at Leerink (TipRanks)
04:00AM	Can a multibillion-dollar deal put Pfizer in the obesity big leagues? (Pharma Voice)
Sep-23-25 06:55PM	Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? (Zacks)
02:13PM	Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer (Insider Monkey)
12:16PM	Can PFE Successfully Return to the Obesity Space With Metsera Buyout? (Zacks)
05:30AM	This Hated Stock Suddenly Looks Like an Obesity Bargain (The Wall Street Journal)
04:35AM	Company News for Sep 23, 2025 (Zacks)
03:47AM	What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? (Motley Fool)
02:41AM	Heard on the Street Tuesday Recap: Even Tylenol Cant Cool This AI Fever (The Wall Street Journal)
Sep-22-25 11:49PM	Asian shares trade mixed after US stocks set more records (Associated Press Finance) +60.80%
09:41PM	Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles (TheStreet)
06:00PM	Podcast: Nasdaq Leads U.S. Stocks to New Records (The Wall Street Journal)
04:20PM	Stocks to Watch Recap: Nvidia, Oracle, Pfizer, Kenvue, Compass (The Wall Street Journal)
04:12PM	These Stocks Moved the Most Today: Oracle, Nvidia, Metsera, Pfizer, Kenvue, Tesla, Anywhere Real Estate, and More (Barrons.com)
02:53PM	These Stocks Are Moving the Most Today: Oracle, Nvidia, Metsera, Pfizer, Kenvue, Tesla, Anywhere Real Estate, and More (Barrons.com)
01:50PM	Stocks to Watch Monday: Nvidia, Oracle, Pfizer, Kenvue, Compass (The Wall Street Journal)
01:28PM	Why Pfizer Stock Just Popped (Motley Fool)
12:51PM	Pfizer Joins Obesity Drug Race With $5B Metsera Purchase (Bloomberg)
12:26PM	Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn (Pharmaceutical Technology)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FMR LLC	See Remark 1	Sep 02 '25	Sale	36.00	268	9,648	0	Sep 04 02:58 PM
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

NMRA

Neumora Therapeutics Inc

PRME

Prime Medicine Inc

MTSR

Metsera Inc

Upgrade your FINVIZ experience